Cargando…
The Synergistic Effects of 5-Aminosalicylic Acid and Vorinostat in the Treatment of Ulcerative Colitis
Background: The drug 5-aminosalicylic acid (5-ASA) is the first-line therapy for the treatment of patients with mild-to-moderate ulcerative colitis (UC). However, in some cases, 5-ASA cannot achieve the desired therapeutic effects. Therefore, patients have to undergo therapies that include corticost...
Autores principales: | He, Long, Wen, Shuting, Zhong, Zhuotai, Weng, Senhui, Jiang, Qilong, Mi, Hong, Liu, Fengbin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8176098/ https://www.ncbi.nlm.nih.gov/pubmed/34093178 http://dx.doi.org/10.3389/fphar.2021.625543 |
Ejemplares similares
-
Stigmasterol Restores the Balance of Treg/Th17 Cells by Activating the Butyrate-PPARγ Axis in Colitis
por: Wen, Shuting, et al.
Publicado: (2021) -
5-Aminosalicylic acid aggravates colitis mimicking exacerbation of ulcerative colitis
por: Miyoshi, Jun, et al.
Publicado: (2018) -
Astragaloside IV ameliorates experimental autoimmune myasthenia gravis by regulating CD4 + T cells and altering gut microbiota
por: Weng, Senhui, et al.
Publicado: (2023) -
Effectiveness of modified Buzhong Yiqi decoction in treating myasthenia gravis: study protocol for a series of N-of-1 trials
por: Weng, Senhui, et al.
Publicado: (2022) -
Significance of 5-Aminosalicylic Acid Intolerance in the Clinical Management of Ulcerative Colitis
por: Mikami, Yohei, et al.
Publicado: (2023)